Pharmacogenetics is the study of interindividual variations in DNA sequence related to drug response.
Many recent studies have correlated genetic variants in drug metabolizing enzymes with variations in treatment response. Indeed, it has been demonstrated that some genetic mutations in these enzymes can reduce or completely inhibit their activity. As consequence, some mutations can accelerate drug metabolism (e.g. UM) eliminating drugs quicker than foreseen, even before having time to act correctly. Others mutations can reduce metabolizing activity (e.g. PM) producing an abnormal drug accumulation in the body. These polymorphisms, resulting in poor or rapid metabolizers, have mostly been studied in cytochromes CYP2D6, CYP2C9 and CYP2C19 genes.
DNAVision, a leading global provider of pharmacogenetic services, helps pharmaceutical companies and clinical research organizations (CROs) effectively integrate pharmacogenetics into their drug development program and also into the field of personal medicine.
DNAVision provides identification and analysis of genetic polymorphisms in drug metabolizing enzymes, transporters, and targets for pharmaceutical research.
DNAVision is able to provide a complete range of pharmacogenetic services using a powerful combination of sequencing and genotyping methods that have highly proved their robustness and meet high level clinical genotyping requirements (Sanger Sequencing, TaqMan RT...).
Assays targetting critical SNPs of cytochrome genes (CYP2C9, CYP2C19, CYP2D6, CYP2C8...) have been developped and validated. A validation procedure is also available to provide flexible services and assays targetting new mutations.
We guarantee the quality of our results by complying with the international standards required by regulatory authorities. DNAVision is the first laboratory in Europe to be ISO17025 accredited for pharmacogenetics tests. We are also CLIA and CAP accredited.